Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 7/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | S100A4 | P26447 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549468 | 0.82 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL2564460 | 0.81 | ERN1 (0.40) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL2564464 | 0.81 | ERN1 (0.40) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL3040456 | 0.78 | ERN1 (0.64) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL16955573 | 0.77 | ERN1 (0.42) | ERN1CYP2A6PTGDR2ALDH1A1CA12 | |
| SCHEMBL16956615 | 0.77 | ERN1 (0.38) | ERN1CYP2A6ALDH1A1CA12CA9 | |
| SCHEMBL203395 | 0.76 | ERN1 (0.61) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL414267 | 0.76 | ERN1 (0.61) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL16765589 | 0.74 | ERN1 (0.59) | ERN1CYP2A6PTGDR2PTPN1ALDH1A1 | |
| SCHEMBL14416446 | 0.74 | HPGD (0.35) | ERN1ALDH1A1CA12CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038581-A1 | A ONE STEP SYNTHESIS OF 2-SUBSTITUTED BENZO[B]THIOPHENES | INDIAN INSTITUTE OF TECHNOLOGY MADRAS (IIT Madras) (IN) | 2021-03-04 | — | — | WO | claimed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4688785-A1 | 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | Beone Medicines I GmbH (CH) | 2026-02-11 | — | — | EP | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| CN-114929676-B | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | 紫丁香疗法有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-115611883-B | PI3K alpha inhibitor with double-ring structure, and preparation method and application thereof | 生物岛实验室 | 2025-03-28 | — | — | CN | disclosed |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113551-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113536-A2 | TRI- AND BI-CYCLIC HETEROARYL HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272736-A1 | Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | ERN1 4165/4885CYP2A6 1180/4885PTGDR2 219/4885 |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | ERN1 3904/4885CYP2A6 1397/4885PTGDR2 266/4885 |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | ERN1 3904/4885CYP2A6 1397/4885PTGDR2 266/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | ERN1 468/4885CYP2A6 3968/4885PTGDR2 1764/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | ERN1 1059/4885CYP2A6 607/4885PTGDR2 534/4885 |
| US-20050256309-A1 | Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands | HRH3, HRH4, HRH2 | ERN1 4165/4885CYP2A6 1180/4885PTGDR2 219/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | ERN1 490/4885CYP2A6 3968/4885PTGDR2 1410/4885 |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | ERN1 3534/4885CYP2A6 1362/4885PTGDR2 282/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | ERN1 3490/4885CYP2A6 1232/4885PTGDR2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.